May 4, 2022
Brian Culley is the CEO of Lineage Cell Therapeutics which is developing cell therapy for Dry AMD, a common condition and one of the leading causes of blindness, and to restore the functional capacity of hearing and the spine.
Brian explains, "Conceptually, what we're doing is manufacturing the type of cell that has been lost due to aging or disease or trauma, and in doing so, in transplanting those cells, we're looking to restore function. This is what we saw in the setting of the eye, and this is what we're looking to replicate in the setting of the ear."
"Lineage has a fundamental technology that allows us to manufacture these specific cell types. That technology is capable of manufacturing not just auditory neurons and retinal cells, as we talked about today, but we also can manufacture the cells of your spinal cord. We have treated 25 people who suffered a traumatic spinal cord injury, and we are working to replace those cells so that they can regain function, operate their own wheelchair, dress, and feed themselves."
"Everything gets converted, and so we're able to come up with these largely pure populations of specific cell types. We can do it at a meaningful scale. Meaningful meaning you can actually get into a clinical trial and test to see if they work. The hallmark of our technology is being able to manufacture these cells in a way that the FDA expects. Rather than an academic science experiment, we're really trying to think about these as products that are going to reach patients and be used by surgeons and physicians."
@ceo_culley @lineagecell #LineageCellTherapeutics #Biotech #CellTherapy #CellTransplant #RegenerativeMedicine #ReplaceandRestore